Lymphoma News

Advances in pediatric cancer research and treatment over the past 50 years have led to dramatic improvements in survival outcomes for this vulnerable population.

Telemedicine garnered higher satisfaction ratings than in-person visits among patients with cancer in terms of access and care provider concern, according to a study published in Journal of the National Comprehensive Cancer Network.

A cancer survivor who experienced oral mucositis during chemotherapy treatment has designed a device to improve quality of life for patients dealing with this painful side effect.

Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting.

Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer.

An oncology financial navigation intervention decreased financial toxicity among patients with blood cancers and their caregivers, according to study results.

Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results.

Individuals living with HIV historically have been at higher risk for non-Hodgkin lymphoma.

In this edition, elevated cardiotoxicity risk for Black patients after chemotherapy; CV risk factor disparities in childhood cancer survivors; neural network helps identify potential targets for cancer drugs and more.

The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.